Sign in Sign up for free

Last updated: 23 May 2024 at 4:21pm EST

Eran Broshy Net Worth




The estimated Net Worth of Eran Broshy is at least $1.29 Million dollars as of 21 May 2024. Mr. Broshy owns over 8,663 units of Theravance Biopharma Inc stock worth over $186,486 and over the last 16 years he sold TBPH stock worth over $754,310. In addition, he makes $353,379 as Independent Director at Theravance Biopharma Inc.

Mr. Broshy TBPH stock SEC Form 4 insiders trading

Eran has made over 6 trades of the Theravance Biopharma Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 8,663 units of TBPH stock worth $70,170 on 21 May 2024.

The largest trade he's ever made was exercising 9,360 units of Theravance Biopharma Inc stock on 23 May 2023 worth over $75,816. On average, Eran trades about 1,092 units every 91 days since 2009. As of 21 May 2024 he still owns at least 23,023 units of Theravance Biopharma Inc stock.

You can see the complete history of Mr. Broshy stock trades at the bottom of the page.





Eran Broshy biography

Eran Broshy serves as Independent Director of the Company. Mr. Broshy has been an operating executive with Tailwind Capital, a New York based private equity firm, supporting their healthcare investment efforts since September 2015. From March 2013 until August 2015, he worked with Linden Capital Partners and Court Square Capital, both private equity firms, as operating partner and executive advisor, respectively, and from June 2009 until December 2012 he worked with Providence Equity Partners as a senior advisor supporting the private equity firm's healthcare information investment efforts. Mr. Broshy previously served for over a decade as the chief executive officer (until 2008) and chairman of the board of directors (until 2010) of inVentiv Health, Inc., a privately held company (and until August 2010 a Nasdaq listed company) that delivers a broad range of clinical and commercialization services to pharmaceutical and life sciences companies globally. Prior to joining inVentiv, Mr. Broshy was a management consultant with The Boston Consulting Group (BCG) for 14 years, including as the partner responsible for BCG's healthcare practice across the Americas. He also served as president and chief executive officer of Coelacanth Corporation, a privately held biotechnology company. He currently serves on the board of directors of Magellan Health, Inc., a public specialty health care management company, and within the previous five years Mr. Broshy has also served on the board of directors of inVentiv Health, Inc. He also serves as chairman of the board of ERT and of DermaRite, both privately-held healthcare companies, as a member of the Corporation of the Massachusetts Institute of Technology ("MIT"), as well as on the board of directors of the American Jewish Committee NY and the Israel Venture Network. Mr. Broshy holds an M.B.A. from Harvard University, an M.S. in civil engineering from Stanford University, and a B.S. in civil engineering from the Massachusetts Institute of Technology.

What is the salary of Eran Broshy?

As the Independent Director of Theravance Biopharma Inc, the total compensation of Eran Broshy at Theravance Biopharma Inc is $353,379. There are 16 executives at Theravance Biopharma Inc getting paid more, with Rick Winningham having the highest compensation of $5,932,410.



How old is Eran Broshy?

Eran Broshy is 61, he's been the Independent Director of Theravance Biopharma Inc since 2014. There are 9 older and 17 younger executives at Theravance Biopharma Inc. The oldest executive at Theravance Biopharma Inc is Burton Malkiel, 87, who is the Independent Director.

What's Eran Broshy's mailing address?

Eran's mailing address filed with the SEC is C/O CERTARA, INC., 100 OVERLOOK CENTER, SUITE 101, PRINCETON, NJ, 08540.

Insiders trading at Theravance Biopharma Inc

Over the last 11 years, insiders at Theravance Biopharma Inc have traded over $11,619,559 worth of Theravance Biopharma Inc stock and bought 4,008,513 units worth $29,986,832,769,275 . The most active insiders traders include Plc Gsk, Inc. Innoviva,, and Eli Samaha. On average, Theravance Biopharma Inc executives and independent directors trade stock every 57 days with the average trade being worth of $448,635. The most recent stock trade was executed by Eli Samaha on 7 August 2024, trading 999,800 units of TBPH stock currently worth $7,798,440.



What does Theravance Biopharma Inc do?

theravance biopharma is a biopharmaceutical company with one approved product, vibativ® (telavancin), that was discovered and developed internally, a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies.



What does Theravance Biopharma Inc's logo look like?

Theravance Biopharma Inc logo

Complete history of Mr. Broshy stock trades at Magellan Health Inc, Theravance Biopharma Inc, and Certara

Date
#
Company
 Insider
Trans.
Transaction
 Shares Price per share Total value Shares after Source
21 May 2024 CERT Certara, Inc. Eran Broshy
Option 8,663 $16.50 $142,940
21 May 2024
23,023 ↗
21 Aug 2023 CERT Certara, Inc. Eran Broshy
Buy 5,000 $15.81 $79,050
21 Aug 2023
14,360 ↗
23 May 2023 CERT Certara, Inc. Eran Broshy
Option 9,360 $21.01 $196,654
23 May 2023
9,360 ↗
23 Feb 2017 MGLN Magellan Health Inc Eran Broshy
Director
 Sale 4,867 $80.00 $389,360
23 Feb 2017
7,960 ↗
8 Dec 2016 MGLN Magellan Health Inc Eran Broshy
Director
 Sale 2,433 $75.00 $182,475
8 Dec 2016
12,827 ↗
8 Dec 2016 MGLN Magellan Health Inc Eran Broshy
Director
 Sale 2,433 $75.00 $182,475
8 Dec 2016
12,827 ↗


Theravance Biopharma Inc executives and stock owners

Theravance Biopharma Inc executives and other stock owners filed with the SEC include: